

Michael Hallek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5948919/publications.pdf>

Version: 2024-02-01

349
papers

16,980
citations

24978

57
h-index

18606

119
g-index

366
all docs

366
docs citations

366
times ranked

17579
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive genomic profiles of small cell lung cancer. <i>Nature</i> , 2015, 524, 47-53.	13.7	1,634
2	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018, 131, 2745-2760.	0.6	1,069
3	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	5.1	676
4	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2019, 380, 2225-2236.	13.9	599
5	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. <i>Blood</i> , 2016, 127, 208-215.	0.6	571
6	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2016, 17, 928-942.	5.1	529
7	Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 6, 100122.	3.0	452
8	COVID-19 associated pulmonary aspergillosis. <i>Mycoses</i> , 2020, 63, 528-534.	1.8	434
9	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology</i> , The, 2016, 17, 200-211.	5.1	373
10	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. <i>American Journal of Hematology</i> , 2019, 94, 1266-1287.	2.0	352
11	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i> , The, 2016, 388, 565-575.	6.3	328
12	Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1596016.	5.5	318
13	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 1409-1418.	5.1	290
14	Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2016, 34, 1386-1394.	0.8	276
15	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
16	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 49-62.	0.6	244
17	Chronic lymphocytic leukaemia. <i>Lancet</i> , The, 2018, 391, 1524-1537.	6.3	233
18	Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. <i>American Journal of Hematology</i> , 2017, 92, 946-965.	2.0	229

#	ARTICLE	IF	CITATIONS
19	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. <i>American Journal of Hematology</i> , 2015, 90, 446-460.	2.0	212
20	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1188-1200.	5.1	208
21	Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1391-1402.	0.8	177
22	Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2018, 9, 727.	5.8	160
23	Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy. <i>Cell</i> , 2014, 156, 590-602.	13.5	155
24	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. <i>American Journal of Hematology</i> , 2021, 96, 1679-1705.	2.0	150
25	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019, 134, 111-122.	0.6	145
26	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. <i>American Journal of Hematology</i> , 2013, 88, 803-816.	2.0	143
27	Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. <i>Journal of Clinical Oncology</i> , 2016, 34, 3758-3765.	0.8	142
28	First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group. <i>Blood</i> , 2009, 114, 535-535.	0.6	142
29	Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. <i>Blood</i> , 2014, 124, 2196-2202.	0.6	138
30	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	13.5	138
31	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 121-128.	0.7	133
32	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	3.2	127
33	Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, 879-883.	1.7	126
34	Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. <i>Blood</i> , 2016, 128, 395-404.	0.6	112
35	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 2702-2705.	0.6	108
36	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017, 58, 1630-1639.	0.6	102

#	ARTICLE	IF	CITATIONS
37	Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. <i>Haematologica</i> , 2014, 99, 1095-1100.	1.7	101
38	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. <i>Blood</i> , 2016, 127, 2847-2855.	0.6	100
39	Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. <i>Blood</i> , 2013, 122, 3723-3734.	0.6	99
40	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008, 112, 325-325.	0.6	99
41	Characterization of tumor-associated B-cell subsets in patients with colorectal cancer. <i>Oncotarget</i> , 2014, 5, 4651-4664.	0.8	98
42	Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. <i>EMBO Molecular Medicine</i> , 2021, 13, e14150.	3.3	98
43	Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. <i>Oncolmmunology</i> , 2016, 5, e1150399.	2.1	94
44	Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1215-1228.	5.1	94
45	PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 223-234.	5.1	93
46	Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group. <i>Leukemia and Lymphoma</i> , 2016, 57, 789-796.	0.6	87
47	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
48	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020, 135, 2402-2412.	0.6	83
49	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. <i>Nature Communications</i> , 2020, 11, 363.	5.8	75
50	Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 4049-4060.	0.8	74
51	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	0.6	72
52	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 574-583.	0.6	69
53	Physical exercise modulates the homeostasis of human regulatory T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1607-1610.e8.	1.5	65
54	Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. <i>Blood</i> , 2015, 126, 2646-2649.	0.6	64

#	ARTICLE	IF	CITATIONS
55	LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2016, 30, 610-622.	7.7	64
56	Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. <i>Blood</i> , 2017, 130, 1477-1480.	0.6	63
57	A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. <i>Blood</i> , 2018, 131, 955-962.	0.6	61
58	Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. <i>Scientific Reports</i> , 2019, 9, 3631.	1.6	57
59	Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2008, 112, 330-330.	0.6	54
60	OCTET [®] CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2016, 96, 27-35.	1.1	52
61	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCLnet). <i>Blood</i> , 2012, 120, 151-151.	0.6	52
62	Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2577-2590.	2.0	49
63	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Oncotarget</i> , 2016, 5, e1100789.	2.1	45
64	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. <i>Lancet Haematology</i> , 2017, 4, e475-e486.	2.2	45
65	RIG-I activation induces the release of extracellular vesicles with antitumor activity. <i>Oncotarget</i> , 2016, 5, e1219827.	2.1	44
66	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2020, 105, 2598-2607.	1.7	44
67	Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53. <i>Theranostics</i> , 2019, 9, 6047-6062.	4.6	43
68	CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, <i>in vitro</i> . <i>Oncotarget</i> , 2016, 7, 30523-30535.	0.8	43
69	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 256-262.	1.7	42
70	Discovery of Candidate DNA Methylation Cancer Driver Genes. <i>Cancer Discovery</i> , 2021, 11, 2266-2281.	7.7	42
71	Tropism-modified AAV Vectors Overcome Barriers to Successful Cutaneous Therapy. <i>Molecular Therapy</i> , 2014, 22, 929-939.	3.7	41
72	17p Deletion Predicts for Inferior Overall Survival after Fludarabine - Based First Line Therapy in Chronic Lymphocytic Leukemia: First Analysis of Genetics in the CLL4 Trial of the GCLLSG. <i>Blood</i> , 2005, 106, 715-715.	0.6	41

#	ARTICLE	IF	CITATIONS
73	The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 177-187.	0.6	40
74	Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2017, 8, 153.	5.8	39
75	COVID-19 among fit patients with CLL treated with venetoclax-based combinations. <i>Leukemia</i> , 2020, 34, 2225-2229.	3.3	39
76	Management of chronic lymphocytic leukemia. <i>Haematologica</i> , 2014, 99, 965-972.	1.7	38
77	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 278-284.	2.0	38
78	CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 1161-1172.	3.3	38
79	Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. <i>Leukemia</i> , 2020, 34, 2038-2050.	3.3	38
80	Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study. <i>British Journal of Ophthalmology</i> , 2016, 101, bjophthalmol-2015-307666.	2.1	36
81	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 176, 618-628.	1.2	36
82	First manifestation of adult-onset Still's disease after COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e319-e321.	2.2	36
83	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (R _{Ve} , G _{Ve} , G _{IVe}) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 71-71.	0.6	36
84	Ultrasound-guided core needle biopsies for workup of lymphadenopathy and lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 379-386.	1.1	35
85	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 715-722.e6.	0.2	35
86	The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. <i>Future Oncology</i> , 2015, 11, 1895-1903.	1.1	34
87	Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2015, 100, 1451-1459.	1.7	34
88	Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 138-150.	0.9	33
89	NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. <i>International Journal of Cancer</i> , 2018, 142, 322-333.	2.3	33
90	Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment - A Systematic Review. <i>Breast Care</i> , 2018, 13, 380-385.	0.8	33

#	ARTICLE	IF	CITATIONS
91	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. HemaSphere, 2019, 3, e287.	1.2	33
92	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 2019, 133, 494-497.	0.6	32
93	Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). HemaSphere, 2020, 4, e336.	1.2	31
94	Prognostication of chronic lymphocytic leukemia in the era of new agents. Hematology American Society of Hematology Education Program, 2016, 2016, 149-155.	0.9	30
95	The proteomic landscape of small urinary extracellular vesicles during kidney transplantation. Journal of Extracellular Vesicles, 2020, 10, e12026.	5.5	30
96	High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 2020, 135, 866-870.	0.6	30
97	Obinutuzumab (GA-101), ibrutinib, and venetoclax (G1Ve) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 2022, 139, 1318-1329.	0.6	30
98	Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene, 2018, 37, 5682-5693.	2.6	29
99	Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). European Journal of Haematology, 2016, 96, 9-18.	1.1	28
100	Antigen-presenting human B cells are expanded in inflammatory conditions. Journal of Leukocyte Biology, 2017, 101, 577-587.	1.5	28
101	Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. Eurosurveillance, 2017, 22, .	3.9	28
102	State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia. Oncology Research and Treatment, 2016, 39, 25-32.	0.8	27
103	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301.	3.2	27
104	CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncology, 2018, 14, 499-513.	1.1	27
105	Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.. Blood, 2009, 114, 880-880.	0.6	27
106	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.6	27
107	Therapy of chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2010, 23, 85-96.	0.7	26
108	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncology, The, 2019, 20, 1576-1586.	5.1	26

#	ARTICLE	IF	CITATIONS
109	New roles for B cell receptor associated kinases: when the B cell is not the target. <i>Leukemia</i> , 2019, 33, 576-587.	3.3	26
110	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3188-3197.	0.6	26
111	Veno-venous extracorporeal membrane oxygenation (vv-ECMO) for severe respiratory failure in adult cancer patients: a retrospective multicenter analysis. <i>Intensive Care Medicine</i> , 2022, 48, 332-342.	3.9	25
112	Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. <i>Haematologica</i> , 2020, 105, 1379-1390.	1.7	24
113	Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. <i>Leukemia</i> , 2020, 34, 1038-1051.	3.3	24
114	Organometallic nucleosides induce non-classical leukemic cell death that is mitochondrial-ROS dependent and facilitated by TCL1-oncogene burden. <i>Molecular Cancer</i> , 2015, 14, 114.	7.9	23
115	Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2017, 5, 730-743.	1.6	23
116	The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. <i>Leukemia</i> , 2020, 34, 296-300.	3.3	23
117	A Retrospective Analysis of <i>Pneumocystis Jirovecii</i> Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016, 128, 3705-3705.	0.6	23
118	SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 562-565.	3.3	23
119	The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. <i>Future Oncology</i> , 2015, 11, 51-59.	1.1	22
120	Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 357-362.	0.9	22
121	Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin. <i>FASEB Journal</i> , 2017, 31, 526-543.	0.2	21
122	Early Palliative Care: Pro, but Please Be Precise!. <i>Oncology Research and Treatment</i> , 2019, 42, 11-18.	0.8	21
123	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50 Years or Older with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 488-495.	2.0	21
124	Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer. <i>Trends in Molecular Medicine</i> , 2014, 20, 72-82.	3.5	20
125	Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	20
126	Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 2144-2154.	1.7	20

#	ARTICLE	IF	CITATIONS
127	Evaluation of a complex integrated, cross-sectoral psycho-oncological care program (isPO): a mixed-methods study protocol. <i>BMJ Open</i> , 2020, 10, e034141.	0.8	20
128	Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 716-719.	1.3	20
129	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7004-7004.	0.8	20
130	Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination. <i>Infection</i> , 2022, 50, 1399-1404.	2.3	20
131	Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2016, 97, 253-260.	1.1	19
132	Optimizing frontline therapy of CLL based on clinical and biological factors. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 338-345.	0.9	19
133	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 2183-2194.	3.3	19
134	Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. <i>Blood</i> , 2016, 128, 3227-3227.	0.6	19
135	<sc>FLAMSA</sc> reducedâ€intensity conditioning is equally effective in <sc>AML</sc> patients with primary induction failure as well as in first or second complete remission. <i>European Journal of Haematology</i> , 2016, 96, 475-482.	1.1	18
136	Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 5, e1211220.	2.1	18
137	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARSâ€CoVâ€2â€Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	1.2	18
138	Supervised pelvic floor muscle exercise is more effective than unsupervised pelvic floor muscle exercise at improving urinary incontinence in prostate cancer patients following radical prostatectomy â€“ a systematic review and meta-analysis. <i>Disability and Rehabilitation</i> , 2022, 44, 5374-5385.	0.9	18
139	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. <i>Blood</i> , 2019, 134, 36-36.	0.6	18
140	No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2007, 110, 629-629.	0.6	18
141	Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	18
142	Immunological effects in patients with steroidâ€refractory graftâ€versusâ€host disease following treatment with basiliximab, a <sc>CD</sc>25 monoclonal antibody. <i>European Journal of Haematology</i> , 2016, 97, 121-127.	1.1	17
143	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50â€yearsâ€“ a report from the EBMT acute leukemia working party. <i>Journal of Hematology and Oncology</i> , 2016, 9, 65.	6.9	17
144	Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. <i>Leukemia and Lymphoma</i> , 2016, 57, 1291-1299.	0.6	17

#	ARTICLE	IF	CITATIONS
145	Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7211.	1.8	17
146	Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4393-4393.	0.6	17
147	Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients. <i>In Vivo</i> , 2018, 32, 819-824.	0.6	16
148	Sleep problems and their interaction with physical activity and fatigue in hematological cancer patients during onset of high dose chemotherapy. <i>Supportive Care in Cancer</i> , 2022, 30, 167-176.	1.0	16
149	Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harboring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). <i>Blood</i> , 2018, 132, 694-694.	0.6	16
150	Subcutaneous Alemtuzumab Combined with Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT In CLL with 17p- or Refractory to Fludarabine â€” Interim Analysis of the CLL20 Trial of the GCLLSG and FCGCLL/MW. <i>Blood</i> , 2010, 116, 920-920.	0.6	16
151	New treatment approaches in CLL: Challenges and opportunities in the elderly. <i>Journal of Geriatric Oncology</i> , 2016, 7, 375-382.	0.5	15
152	Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells. <i>Haematologica</i> , 2017, 102, e100-e103.	1.7	15
153	Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 295-304.	2.0	15
154	How to approach CLL in clinical practice. <i>Hematological Oncology</i> , 2019, 37, 38-42.	0.8	15
155	New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabineâ€”mitoxantroneâ€”cyclophosphamideâ€”alemtuzumab induction followed by alemtuzumab maintenance. <i>Leukemia and Lymphoma</i> , 2019, 60, 649-657.	0.6	15
156	Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. <i>Cell Reports</i> , 2020, 31, 107568.	2.9	15
157	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	5.8	15
158	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 420-425.	0.6	14
159	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 255-263.	1.3	14
160	MARCKS affects cell motility and response to BTK inhibitors in CLL. <i>Blood</i> , 2021, 138, 544-556.	0.6	14
161	Comparison of the Efficacy and Toxicity of Fludarabine (F) in First Line Therapy of Younger Versus Elderly Patients (Pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Meta-Analysis of Two Phase III Trials of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2005, 106, 717-717.	0.6	14
162	FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 399-407.	0.6	13

#	ARTICLE	IF	CITATIONS
163	Acquisition of the recurrent Gly101Val mutation in <i>BCL2</i> confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.). <i>Haematologica</i> , 2019, 104, e540-e540.	1.7	13
164	Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9211.	1.8	13
165	Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSC). <i>Blood</i> , 2007, 110, 625-625.	0.6	13
166	Quantitative MRD Assessments Predict Progression Free Survival in CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab – a Prospective Analysis in 471 Patients from the Randomized GCLLSC CLL8 Trial. <i>Blood</i> , 2008, 112, 326-326.	0.6	13
167	Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. <i>Blood</i> , 2015, 126, LBA-6-LBA-6.	0.6	13
168	Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes – results of a retrospective analysis from a German university hospital. <i>Annals of Hematology</i> , 2022, 101, 389-395.	0.8	13
169	Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1130-1139.	0.6	12
170	Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. <i>Annals of Hematology</i> , 2017, 96, 479-487.	0.8	12
171	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018, 59, 1614-1623.	0.6	12
172	The economic burden of endoscopic treatment for anastomotic leaks following oncological Ivor Lewis esophagectomy. <i>PLoS ONE</i> , 2019, 14, e0221406.	1.1	12
173	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019, 60, 1438-1446.	0.6	12
174	Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicentre, open-label phase-II trial. <i>Haematologica</i> , 2021, 106, 543-554.	1.7	12
175	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). <i>Blood</i> , 2016, 128, 229-229.	0.6	12
176	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3230-3230.	0.6	12
177	Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. <i>PLoS ONE</i> , 2016, 11, e0160871.	1.1	12
178	Long-Term Follow-up of Rituximab Treatment of Non-Familial Idiopathic Thrombotic Thrombocytopenic Purpura (TTP). <i>Blood</i> , 2009, 114, 3513-3513.	0.6	12
179	Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany. <i>BMC Health Services Research</i> , 2022, 22, 543.	0.9	12
180	Initial therapy of chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 241-250.	0.8	11

#	ARTICLE	IF	CITATIONS
181	Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).. Blood, 2006, 108, 482-482.	0.6	11
182	Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG. Blood, 2010, 116, 2427-2427.	0.6	11
183	Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. Blood, 2016, 128, 192-192.	0.6	11
184	Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 2016, 128, 4382-4382.	0.6	11
185	The Treatment of Chronic Lymphatic Leukemia. Deutsches Ärztblatt International, 2019, 116, 41-46.	0.6	11
186	Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany. Blood Cancer Journal, 2021, 11, 174.	2.8	11
187	On the architecture of translational research designed to control chronic lymphocytic leukemia. Hematology American Society of Hematology Education Program, 2018, 2018, 1-8.	0.9	10
188	Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica, 2019, 104, 1798-1803.	1.7	10
189	COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia. European Journal of Haematology, 2020, 105, 508-511.	1.1	10
190	Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma. Frontiers in Immunology, 2020, 11, 398.	2.2	10
191	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2021, 137, 2267-2271.	0.6	10
192	Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients. BMC Cancer, 2021, 21, 719.	1.1	10
193	Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009) Tj ETQq1 1 0784314 ngBT /Ov	1.1	10
194	Micro-RNA networks in T-cell prolymphocytic leukemia reflect T-cell activation and shape DNA damage response and survival pathways. Haematologica, 2022, 107, 187-200.	1.7	10
195	Targeted Therapy of CLL. Oncology Research and Treatment, 2016, 39, 768-778.	0.8	9
196	Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review. Therapeutic Advances in Hematology, 2017, 8, 197-205.	1.1	9
197	Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. European Journal of Haematology, 2017, 98, 254-262.	1.1	9
198	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Journal of Molecular Diagnostics, 2020, 22, 1300-1307.	1.2	9

#	ARTICLE	IF	CITATIONS
199	Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2. <i>Cancers</i> , 2020, 12, 2303.	1.7	9
200	Invasive Aspergillosis in Patients Treated With Ibrutinib. <i>HemaSphere</i> , 2020, 4, e309.	1.2	9
201	TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSC. <i>Blood</i> , 2009, 114, 1267-1267.	0.6	9
202	11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. <i>Blood</i> , 2016, 128, 2042-2042.	0.6	9
203	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in Elderly Patients with Comorbidities: Analysis of the CLL11 Study Population. <i>Blood</i> , 2016, 128, 4401-4401.	0.6	9
204	CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. <i>Blood</i> , 2016, 128, 640-640.	0.6	9
205	Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (<sc>CLL</sc>): results of a multicentre phase <sc>II</sc> study of the German <sc>CLL</sc> Study Group (<sc>GCLLSG</sc>). <i>British Journal of Haematology</i> , 2012, 158, 238-241.	1.2	8
206	Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia. <i>Seminars in Hematology</i> , 2014, 51, 235-248.	1.8	8
207	Cytotoxicity of the <sc>CD</sc>37 antibody <sc>BI</sc> 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or <sc>PI</sc>3K inhibitors. <i>British Journal of Haematology</i> , 2016, 173, 791-794.	1.2	8
208	Management of unfit elderly patients with chronic lymphocytic leukemia. <i>European Journal of Internal Medicine</i> , 2018, 58, 7-13.	1.0	8
209	Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital. <i>Annals of Hematology</i> , 2019, 98, 2605-2607.	0.8	8
210	Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. <i>Haematologica</i> , 2020, 105, e519.	1.7	8
211	Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States. <i>Blood</i> , 2019, 134, 4741-4741.	0.6	8
212	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016, 128, 2054-2054.	0.6	8
213	Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in E μ -TCL1 mice. <i>Blood Advances</i> , 2020, 4, 6106-6116.	2.5	8
214	Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 867042.	2.0	8
215	Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the microenvironmental dialogue. <i>British Journal of Haematology</i> , 2017, 178, 949-953.	1.2	7
216	Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 183, 727-735.	1.2	7

#	ARTICLE	IF	CITATIONS
217	Durable remissions following combined targeted therapy in patients with CLL harboring <i>TP53</i> deletions and/or mutations. <i>Blood</i> , 2021, 138, 1805-1816.	0.6	7
218	Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.. <i>Blood</i> , 2006, 108, 483-483.	0.6	7
219	Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. <i>Blood</i> , 2012, 120, 433-433.	0.6	7
220	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	0.6	7
221	Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS-CoV-2 mRNA vaccination. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	7
222	A Novel Recombinant Anti-CD22 Immunokine Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 971-984.	1.9	6
223	On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission. <i>Clinical Infectious Diseases</i> , 2017, 65, 1404-1406.	2.9	6
224	Analysis of ITGB2 rare germ line variants in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 130, 2443-2444.	0.6	6
225	HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?. <i>Infection</i> , 2019, 47, 293-300.	2.3	6
226	Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, e224-e226.	1.7	6
227	Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial. <i>British Journal of Haematology</i> , 2019, 184, 833-836.	1.2	6
228	Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. <i>Leukemia</i> , 2020, 34, 1177-1181.	3.3	6
229	Bridging antifungal prophylaxis with 50mg or 100mg micafungin in allogeneic stem cell transplantation: A retrospective analysis. <i>European Journal of Haematology</i> , 2020, 104, 291-298.	1.1	6
230	Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the Eμ-TCL1 Transgenic Mouse Model. <i>Cancers</i> , 2020, 12, 1980.	1.7	6
231	Relevant Cytokines in the B Cell Lymphoma Micro-Environment. <i>Cancers</i> , 2020, 12, 2525.	1.7	6
232	Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).. <i>Blood</i> , 2007, 110, 2038-2038.	0.6	6
233	Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2022, 6, e692.	1.2	6
234	Venetoclax after idelalisib: relevant progress for CLL. <i>Blood</i> , 2018, 131, 1632-1633.	0.6	5

#	ARTICLE	IF	CITATIONS
235	Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology, 2019, 94, 1002-1006.	2.0	5
236	Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. American Journal of Hematology, 2021, 96, 1112-1119.	2.0	5
237	A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Entospletinib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 4297-4297.	0.6	5
238	Fibromodulin as a Novel Tumor-Associated Antigen (TAA) in Chronic Lymphocytic Leukemia (CLL) Which Allows Expansion of Specific CD8+ Autologous T Lymphocytes.. Blood, 2004, 104, 175-175.	0.6	5
239	Impact of Different Chemotherapy Regimen in Comorbid Patients with Advanced Chronic Lymphocytic Leukemia: Metaanalysis of Two Phase-III-Trials of the German CLL Study Group.. Blood, 2006, 108, 2840-2840.	0.6	5
240	Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?. European Journal of Haematology, 2022, 108, 369-378.	1.1	5
241	KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematology, 2022, 9, e133-e142.	2.2	5
242	Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia. Cancer Journal (Sudbury, Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	4
243	Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group. Leukemia and Lymphoma, 2016, 57, 596-603.	0.6	4
244	Regulatory B10 cells display an altered homeostasis in acute graft-versus-host disease. European Journal of Haematology, 2017, 98, 128-133.	1.1	4
245	What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?. Annals of Hematology, 2021, 100, 1377-1389.	0.8	4
246	CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin. Frontiers in Cell and Developmental Biology, 2021, 9, 698503.	1.8	4
247	Altered DNA Methylation Profiles in SF3B1 Mutated CLL Patients. International Journal of Molecular Sciences, 2021, 22, 9337.	1.8	4
248	Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer. European Journal of Cancer, 2021, 155, 281-290.	1.3	4
249	CHOP Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Hemolytic Anemia (AIHA) or Richter's Transformation (RT): First Interim Analysis of a Phase II Trial of the German CLL Study Group (GCLLSG).. Blood, 2005, 106, 2126-2126.	0.6	4
250	Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). Blood, 2016, 128, 2044-2044.	0.6	4
251	ROR-1 Is a Highly Discriminative Marker in Flow Cytometric Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL). Blood, 2016, 128, 3197-3197.	0.6	4
252	The Para-Isomer of Nitric Oxide Donating Acetylsalicylic Acid (p-NO-ASA) Induces Apoptosis in Chronic Lymphocytic Leukemia (CLL) In Vitro and In Vivo without Gross Systemic Toxicities.. Blood, 2009, 114, 3783-3783.	0.6	4

#	ARTICLE	IF	CITATIONS
253	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2634-2634.	0.6	4
254	Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. <i>Leukemia</i> , 2022, 36, 2125-2128.	3.3	4
255	Chemoimmunotherapy towards real progress in the treatment of chronic lymphocytic leukemia. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 338-339.	4.3	3
256	Current strategies to create tailored and risk-adapted therapies for CLL patients. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 111-121.	0.7	3
257	Pathogenesis, Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Exciting Times. <i>Oncology Research and Treatment</i> , 2016, 39, 8-8.	0.8	3
258	FimH-based display of functional eukaryotic proteins on bacteria surfaces. <i>Scientific Reports</i> , 2019, 9, 8410.	1.6	3
259	Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541983235.	0.8	3
260	CD74 is dispensable for development of chronic lymphocytic leukemia in E μ -TCL1 transgenic mice. <i>Leukemia and Lymphoma</i> , 2020, 61, 2799-2810.	0.6	3
261	Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E457-E460.	2.0	3
262	Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial. <i>Blood</i> , 2019, 134, 4315-4315.	0.6	3
263	Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial. <i>Blood</i> , 2010, 116, 2357-2357.	0.6	3
264	TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study). <i>Blood</i> , 2013, 122, 1638-1638.	0.6	3
265	Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT. <i>Blood</i> , 2013, 122, 545-545.	0.6	3
266	Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. <i>Blood</i> , 2016, 128, 682-682.	0.6	3
267	High Lymphoid Enhancer-Binding Factor-1 (LEF1) Expression Is Associated with ZAP70 Positivity, Requirement of Treatment, and Fibromodulin (FMOD) Expression In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 1715-1715.	0.6	3
268	B-Cell Receptor-Mediated Glucosylceramide Synthesis Protects Primary CLL Cells From Ceramide-Dependent Apoptosis. <i>Blood</i> , 2011, 118, 1766-1766.	0.6	3
269	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 72-72.	0.6	3
270	Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). <i>Haematologica</i> , 2021, 106, 2834-2844.	1.7	3

#	ARTICLE	IF	CITATIONS
271	Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2022, 6, e729.	1.2	3
272	Towards improved frontline treatment of CLL in the elderly. <i>Lancet</i> , The, 2015, 385, 1814-1815.	6.3	2
273	Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?. <i>Leukemia and Lymphoma</i> , 2016, 57, 987-990.	0.6	2
274	Role and timing of new drugs in CLL. <i>Hematological Oncology</i> , 2017, 35, 30-32.	0.8	2
275	Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. <i>British Journal of Haematology</i> , 2017, 179, 342-346.	1.2	2
276	Der Ältere Krebspatient - Herausforderungen im Krankenhaus und in der Praxis. <i>Oncology Research and Treatment</i> , 2018, 41, 2-26.	0.8	2
277	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in Real-Life Outside of Clinical Trials. <i>Anticancer Research</i> , 2019, 39, 2591-2598.	0.5	2
278	Economic Impact of the Introduction of Outpatient Medical Specialist Care (ASV) of Gastrointestinal Cancer Patients from a German Hospital Management Perspective. <i>Oncology Research and Treatment</i> , 2020, 43, 498-505.	0.8	2
279	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2021, , .	1.7	2
280	Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). , 2017, , .		2
281	Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial. <i>Blood</i> , 2019, 134, 4305-4305.	0.6	2
282	Final Results of a Phase Ib Trial of Ataccept to Neutralize APRIL and BLYS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009, 114, 2373-2373.	0.6	2
283	Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2009, 114, 3438-3438.	0.6	2
284	Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch.. <i>Blood</i> , 2009, 114, 877-877.	0.6	2
285	Early Autologous Stem Cell Transplantation (autoSCT) May Overcome the Adverse Impact of Del 11q- in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3 Trial.. <i>Blood</i> , 2009, 114, 879-879.	0.6	2
286	Novel X-Linked Inhibitor of Apoptosis (XIAP) Inhibiting Compound as Sensitizer for TRAIL-Mediated Apoptosis In Chronic Lymphocytic Leukemia with Poor Prognosis. <i>Blood</i> , 2010, 116, 1375-1375.	0.6	2
287	Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2011, 118, 2863-2863.	0.6	2
288	Relapsed disease and aspects of undetectable MRD and treatment discontinuation. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 482-489.	0.9	2

#	ARTICLE	IF	CITATIONS
289	Initial Therapy of Chronic Lymphocytic Leukemia. <i>Hematologic Malignancies</i> , 2019, , 79-96.	0.2	2
290	Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2019, 134, 3046-3046.	0.6	2
291	The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. <i>Blood</i> , 2020, 136, 3-4.	0.6	2
292	Evaluation of a Prognostic Epigenetic Classification System in Chronic Lymphocytic Leukemia Patients. <i>Biomarker Insights</i> , 2022, 17, 117727192110679.	1.0	2
293	A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. <i>EJHaem</i> , 2022, 3, 492-506.	0.4	2
294	Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual. <i>Leukemia Research</i> , 2014, 38, 284-285.	0.4	1
295	Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective. <i>European Journal of Haematology</i> , 2017, 98, 169-176.	1.1	1
296	International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278.	0.2	1
297	Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4430-4430.	0.6	1
298	Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). <i>Blood</i> , 2018, 132, 1859-1859.	0.6	1
299	Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group. <i>Blood</i> , 2019, 134, 3040-3040.	0.6	1
300	Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.. <i>Blood</i> , 2006, 108, 2730-2730.	0.6	1
301	Standardized MRD Flow and ASO IGH RQ-PCR for MRD Quantification in CLL Patients after Rituximab-Containing Immunochemotherapy – a Comparative Analysis in 574 Samples from the Randomized GCLLSG CLL8 Trial. <i>Blood</i> , 2008, 112, 3139-3139.	0.6	1
302	High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 50-50.	0.6	1
303	NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg. <i>Blood</i> , 2012, 120, 710-710.	0.6	1
304	Loss of TOSO Promotes Richter's Transformation of TCL1A Driven CLL. <i>Blood</i> , 2016, 128, 354-354.	0.6	1
305	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. <i>Blood</i> , 2016, 128, 4376-4376.	0.6	1
306	APT1-Mediated Cross-Talk Between Palmitoylation and Phosphorylation Events of the BCR Pathway Sensitizes CLL Cells Towards BCR-Associated Kinase Inhibitors. <i>Blood</i> , 2016, 128, 4361-4361.	0.6	1

#	ARTICLE	IF	CITATIONS
307	Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2016, 128, 4394-4394.	0.6	1
308	Pooled Analysis of First-Line Treatment with Targeted Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Aged 80 Years and Older. <i>Blood</i> , 2021, 138, 1552-1552.	0.6	1
309	A Novel Autochthonous Mouse Model Serves As a Preclinical Evaluation Platform and Explores Dual BTK and BCL2 Inhibition for Activated B Cell-like Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 712-712.	0.6	1
310	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. <i>Blood</i> , 2021, 138, 2639-2639.	0.6	1
311	Physiologic evaluation in the elderly prior to treatment with chemotherapy. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 620-1.	0.3	1
312	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1794-1805.	3.3	1
313	Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update. <i>Hematologic Malignancies</i> , 2019, , 69-77.	0.2	0
314	Impact of induction chemotherapy on objective and self-perceived cognitive performance in patients suffering from hematological disorders. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-5.	0.6	0
315	Providing care in isolation while awaiting SARS-CoV-2 test results. <i>Medicine (United States)</i> , 2021, 100, e26720.	0.4	0
316	PEG-Interferon for Chronic Phase CML - Still an Option in the Era of Imatinib?.. <i>Blood</i> , 2004, 104, 4662-4662.	0.6	0
317	Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006, 108, 2084-2084.	0.6	0
318	The Para-Isomer of Nitric Oxide-Donating Acetylic Salicylic Acid (p-NO-ASA) Effectively Induces Cell Death in B-Cell Chronic Lymphocytic Leukemia (CLL) Cells at Low Micromolar Concentrations.. <i>Blood</i> , 2008, 112, 1606-1606.	0.6	0
319	Allogeneic Stem Cell Transplantation for Relapsed Hodgkin's Disease - a Single Centre Experience. <i>Blood</i> , 2008, 112, 4431-4431.	0.6	0
320	Deregulation of miRNAs by Epigenetic Silencing Disrupts Suppression of the Oncogene PLAG1 in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 3463-3463.	0.6	0
321	Vascular Endothelial Growth Factor (VEGF) Acts Via Auto- and Paracrine Mechanisms as a Critical Microenvironmental Factor for the Survival of Chronic Lymphocytic Leukemia (CLL) Cells.. <i>Blood</i> , 2009, 114, 4376-4376.	0.6	0
322	Potent Antineoplastic Activity of Two Inhibitors of Lymphoid Enhancer Binding Factor-1 (LEF-1) in Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2009, 114, 885-885.	0.6	0
323	Allogeneic Stem Cell Transplantation for Hodgkin's Disease From Sibling and Unrelated Donors: The German Cooperative Transplantation Study Group Experience.. <i>Blood</i> , 2009, 114, 2293-2293.	0.6	0
324	IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2010, 116, 3609-3609.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Microenvironment Influences Expression of TOSO – a Novel NF-Kappa B Target Gene In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 695-695.	0.6	0
326	Acute Myeloid Leukemia and Survival on the Intensive Care Unit (ICU) - Biology- and Treatment-Related Determinants of Outcome - An Analysis of the AML-CG. Blood, 2010, 116, 2166-2166.	0.6	0
327	B Cell Receptor Stimulation of CLL Cells Leads to Upregulation of IRF4 Proteinexpression Influenced by SNP Expression,. Blood, 2011, 118, 3886-3886.	0.6	0
328	Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.. Blood, 2012, 120, 2874-2874.	0.6	0
329	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with High-Risk AML in Complete Remission: A Survey from the ALWP of the EBMT. Blood, 2015, 126, 3105-3105.	0.6	0
330	Transformation of Chronic Lymphocytic Leukemia Towards Richter’s Syndrome Is Induced By AKT Activation. Blood, 2016, 128, 2031-2031.	0.6	0
331	Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis. Blood, 2016, 128, 5588-5588.	0.6	0
332	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. Blood, 2016, 128, 3504-3504.	0.6	0
333	DNA Damage-Response Pathway in Lymphoma Determines Interactions with Macrophages By Altered PD-L1 Expression and Exosome Formation. Blood, 2018, 132, 275-275.	0.6	0
334	Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 2018, 132, 583-583.	0.6	0
335	Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 2018, 132, 4429-4429.	0.6	0
336	MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. Blood, 2018, 132, 1866-1866.	0.6	0
337	Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG). Blood, 2019, 134, 4293-4293.	0.6	0
338	BIM Regulation Is BTK Dependent and Can be Targeted By Entospletinib in Ibrutinib Refractory Mutants. Blood, 2019, 134, 1765-1765.	0.6	0
339	Lyn Kinase Contributes to the Reprogramming of Fibroblasts Promoting Chronic Lymphocytic Leukemia Progression. Blood, 2019, 134, 4283-4283.	0.6	0
340	Cell line-based assessment of BTK inhibitors. British Journal of Pharmacology, 2020, 177, 2163-2165.	2.7	0
341	Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies. HemaSphere, 2021, 5, e664.	1.2	0
342	The Scaffolding Protein NEDD9 Regulates Chronic Lymphocytic Leukemia Cell Migration Via the CXCR4 - CXCL12 Axis and Promotes Disease Progression. Blood, 2020, 136, 2-2.	0.6	0

#	ARTICLE	IF	CITATIONS
343	BIOM-40. ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE. <i>Neuro-Oncology</i> , 2020, 22, ii10-ii10.	0.6	0
344	Robust Discovery of Candidate DNA Methylation Cancer Drivers. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
345	Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Unstable Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
346	New menus for CLL treatment. <i>Oncology</i> , 2009, 23, 1046, 1051, 1056.	0.4	0
347	Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. <i>Infection</i> , 2022, , 1.	2.3	0
348	The role of minimal residual disease in chronic lymphocytic leukemia.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20, 97-103.	0.3	0
349	Pharmacokinetics and Exposure-Response Analysis of Venetoclax+Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. <i>Advances in Therapy</i> , 0, , .	1.3	0